Literature DB >> 759884

Adriamycin and the heart.

I C Henderson, T E Frei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 759884     DOI： 10.1056/NEJM197902083000610

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  Doxorubicin effects on contractile structures and molecules.

Authors:  R Colombo; A Milzani; A Necco; G Vailati
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

Review 2.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

3.  Noninvasive identification of anthracycline cardiotoxicity: comparison of 123I-MIBG and 123I-BMIPP imaging.

Authors:  Y Takeishi; H Sukekawa; T Sakurai; H Saito; S Nishimura; T Shibu; Y Sasaki; H Tomoike
Journal:  Ann Nucl Med       Date:  1994-08       Impact factor: 2.668

4.  Overexpression of Nd1, a novel Kelch family protein, in the heart of transgenic mice protects against doxorubicin-induced cardiomyopathy.

Authors:  Yuji Matsudo; Yasuyuki Takamori; Lisa Fujimura; Saori Nishio; Kazushi Sasagawa; Issei Komuro; Takeshi Tokuhisa; Masahiko Hatano
Journal:  Transgenic Res       Date:  2006-09-02       Impact factor: 2.788

5.  Phosphorylation of IκBα at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.

Authors:  Jung-Hwan Park; Dae-Sung Yoon; Hye-Jin Choi; Dae-Hyun Hahm; Sang-Muk Oh
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

6.  Evaluation of left ventricular performance in infants and children using radionuclide angiography.

Authors:  J I Brenner; R Moschler; K Baker; M A Berman
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

7.  Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD).

Authors:  S Danhauser-Riedl; E Hausmann; H D Schick; R Bender; H Dietzfelbinger; J Rastetter; A R Hanauske
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

8.  Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants.

Authors:  J F Van Vleet; V J Ferrans; W E Weirich
Journal:  Am J Pathol       Date:  1980-04       Impact factor: 4.307

9.  Concomitant low-dose doxorubicin treatment and exercise.

Authors:  Kathleen Sturgeon; Keri Schadler; Geetha Muthukumaran; Dennis Ding; Akinyemi Bajulaiye; Nicholas J Thomas; Victor Ferrari; Sandra Ryeom; Joseph R Libonati
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-09       Impact factor: 3.619

10.  [Possible prevention of adriamycin-induced cardiomyopathy by verapamil. Results of a pilot study].

Authors:  U Müllerleile; M Garbrecht; P Hanrath; B A Langenstein; K Bieber; W Bleifeld; D K Hossfeld
Journal:  Klin Wochenschr       Date:  1984-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.